Brief: Atossa Therapeutics Announces Expanded Research Agreement With Weill Cornell To Evaluate Synergy Between ADCS And Endoxifen
29/04/2024 13:32
April 29 (Reuters) - Atossa Therapeutics Inc ATOS.O :
* ATOSSA THERAPEUTICS ANNOUNCES EXPANDED RESEARCH AGREEMENT
WITH
WEILL CORNELL MEDICINE TO FURTHER EVALUATE SYNERGY BETWEEN
ANTIBODY DRUG CONJUGATES (ADCS) AND (Z)-ENDOXIFEN
Source text for Eikon: ID:nGNX74K42w
Further company coverage: ATOS.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Atossa Therapeutics
See all newsAtossa Therapeutics Inc reports results for the quarter ended September 30 - Earnings Summary
Atossa Therapeutics Q3 net loss narrows as clinical trial expenses decline
Brief: Atossa Therapeutics Executes Contingent Value Rights Agreement Providing Shareholders Participation In Potential Priority Review Voucher Value
US RESEARCH ROUNDUP-Amrize, Dexcom, Lennar
Atossa Therapeutics Inc reports results for the quarter ended June 30 - Earnings Summary